Topics:

ubmslateCL-logo-ubm

CL Mobile Menu

Meningococcal Vaccines: Which One, For Who, and When?

Meningococcal Vaccines: Which One, For Who, and When?

Headaches following a meningococcal vaccine are not common, but trying to figure out to whom and when some of these vaccines should be given can easily bring one on in any practitioner. As prophylaxis against headaches, here’s a rundown on the available vaccines, at-a-glance:

Trade Name Type

Serogroups
included

Year
licensed
Approved
ages
Menomune Polysacch A, C, W, Y 1981

≥2 y

Menactra Conjugate A, C, W, Y 2005

9 mo - 55 ya

Menveo Conjugate A, C, W, Y 2010 2 mo - 55 ya
MenHibrix Conjugate C, Y, Hib 2012 6 w -18 mo
Trumenba Protein B 2014 10 - 25yb
3-dose series
Bexsero Protein B 2015

10 - 25yb
2-dose series

aMay be given to people age 56 years or older (consult ACIP recommendations). bMay be given to people age 26 years or older (consult ACIP recommendations). 

 

Now let’s get more specific about the two new kids on the block, Trumemba and Bexsero.

1. For which of the following groups is routine meningococcal B (MenB) vaccination not recommended?

A. Individuals with severe combined immunodeficiency disease (SCID)

B. All persons over the age of 10 with functional or anatomic asplenia

C. All persons over the age of 10 with persistent complement component deficiency

D. None of the above; that is, all the above groups should be routinely vaccinated

For answer, discussion, and next question, please click here.

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.